NEWS & COMMENTS

PROHOST    FILTER

Eye  On

GILEAD TO ACQUIRE MYOGEN FOR $2.5 BILLION

GILEAD SCIENCES (GILD) decided to acquire MYOGEN (MYOG). The transaction has already been structured as a two-step acquisition comprised of a cash tender offer for all of the outstanding Myogen common stock at $52.50 per share, followed by a cash merger in which Gilead would acquire any remaining outstanding Myogen common stock at $52.50 per share. Upon completion of the whole process, Myogen will become a wholly-owned subsidiary of Gilead. The value of the transaction is approximately $2.5 billion.

Is the acquisition worth the $2.5 billion?

Read Prohost assessment of the deal and about the real meaning of Gilead’s projections about its effects on its future income in Prohost E-Letter that will be posted Tureesday morning on Prohost web and e-mailed to the subscribers of this frequent letter.

READ THE PRESS RELEASE: Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm